Home > News > Altair Nanotechnologies Licenses RenaZorb(TM)
January 31st, 2005
Altair Nanotechnologies Licenses RenaZorb(TM)
Abstract:
Altair Nanotechnologies announced today that a licensing agreement has been signed with California-based Spectrum Pharmaceuticals, giving Spectrum the exclusive worldwide rights for human therapeutic and diagnostic applications to develop, market and sell its RenaZorb™ product line. Altair's RenaZorb™ products, which target an emerging billion-dollar-plus market, are for phosphate control in patients with Chronic Kidney Disease (CKD) and hyperphosphatemia, high phosphate levels in blood, associated with End Stage Renal Disease (ESRD). These products are non-aluminum-, non-calcium-based phosphate binders, which utilize Altair's proprietary lanthanum nanomaterial technology.
Source:
marketwire
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025
ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||